Project Grant K01AI183927
Award Date
8/6/24
Completion Date
7/31/27
Dollars Obligated
$388K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
This is a Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855). The grant aims to explore the impact of gender-affirming hormone therapy on HIV viral dynamics and immune responses in transgender women. The $2,314,470 award will fund research over a 5-year period from November 2024 to October 2029. The principal investigator is leveraging two cohorts of transgender women, including a...
This Project Grant award, valued at $3,302,677.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will support research at Oregon Health & Science University (OHSU) focused on using multimodal positron emission tomography (PET) imaging to directly visualize sites of simian immunodeficiency virus (SIV) persistence and identify early tissue foci of viral rebound in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $340,712 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Rochester. The grant, titled "Evaluating the Role of Monocytes in the Development of an Effective HIV Vaccine Response", aims to investigate the role of monocyte subpopulations in regulating the antibody response to HIV vaccines. The research project, scheduled for completion by June 30, 2027,...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,564,570 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on identifying drivers of genital inflammation and HIV acquisition in women living in sub-Saharan Africa. The project will run from August 2024 through June 2029. The grant supports several key products and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $820,845 to New York University School of Medicine to conduct research aimed at improving HIV outcomes across diverse settings and subgroups in the U.S. HIV epidemic. The research will use mathematical modeling to simulate alternative ways to distribute resources across interventions, settings, and target...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,547,482.00 to Trustees of Dartmouth College to conduct research aimed at improving the antiviral activity of broadly neutralizing antibodies (BNABs) against HIV. The research will focus on two strategies to enhance BNAB efficacy: Fc engineering to improve BNAB effector functions, and the use of BNAB combinations....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $490,788 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The grant, titled "Quantifying Genomic and Pharmacometabolomic Differences in Antiretroviral Exposure in MACS/WIHS Combined Cohort Study", aims to identify genetic and metabolic factors that influence the plasma concentrations and associated...
This Project Grant award of $1,454,386.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental research to better understand the epigenetic regulation of the HIV-1 viral RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its linkage to modulating host innate immune signaling, with the goal of developing new treatments to neutralize deleterious...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,283 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, effective August 16, 2024 through July 31, 2029, will support research to investigate the effects of targeting immune activation and intestinal barrier on comorbidities in people living with HIV. The research aims to advance...